BioCentury | May 10, 2019
Emerging Company Profile

HopeMed: Targeting PRLR for chronic diseases

HopeMed spun out of Peking University last month with a mAb against the prolactin receptor from Bayer that could provide a safe alternative to competing therapies for endometriosis and alopecia. Hope Medicine Inc. has exclusive...
BioCentury | Apr 19, 2019

Hope for China’s academic spinouts

Peking University spinout Hope Medicine is one of the latest examples of a trend that sees academics from Chinese universities increasingly taking top roles in a biotech sector traditionally led by MNC veterans. The start-up...
BC Week In Review | Apr 11, 2019
Company News

Hope Medicine in-licenses Bayer’s BAY 1158061

Hope Medicine gained exclusive, worldwide rights from Bayer to develop and commercialize BAY 1158061 to treat male and female pattern hair loss, endometriosis and other chronic diseases with dysregulated PRL signaling. Hope Medicine Inc. (Beijing,...
BC Extra | Apr 10, 2019
Financial News

Venture roundup: Inozyme, Cullgen, EdiGENE, Hope Medicine

At least four biotechs announced venture rounds this week, including rare mineralization disorders play Inozyme and three companies backed by Asian investors. Inozyme Pharma Inc. (Boston, Mass.) raised $67 million in a series A2 round...
BC Week In Review | Jul 25, 2016
Clinical News

XOMA 213: Phase II started

Xoma began an open-label, Spanish Phase II proof-of-concept (POC) trial to evaluate 2 dose levels of IV XOMA 213 in up to 35 women who wish to suppress lactation immediately after delivery. Xoma said it...
BC Innovations | Aug 21, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Liver cancer Prolactin (PRL); PRL receptor (PRLR) In vitro and mouse studies suggest increasing PRL signaling could help prevent hepatocellular carcinoma (HCC). In human and...
BioCentury | Oct 9, 2006
Tools & Techniques

A new growth hormone

Neuren Pharmaceuticals Ltd. has preclinical data suggesting that its isoform of human growth hormone, dubbed NNZ-3006 , could be used to treat obesity in adults without the side effects that have prevented the use of the...
Items per page:
1 - 7 of 7